JP2005526028A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005526028A5 JP2005526028A5 JP2003566002A JP2003566002A JP2005526028A5 JP 2005526028 A5 JP2005526028 A5 JP 2005526028A5 JP 2003566002 A JP2003566002 A JP 2003566002A JP 2003566002 A JP2003566002 A JP 2003566002A JP 2005526028 A5 JP2005526028 A5 JP 2005526028A5
- Authority
- JP
- Japan
- Prior art keywords
- aliphatic
- ring
- benzimidazol
- optionally substituted
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001931 aliphatic group Chemical group 0.000 claims description 128
- 229910052739 hydrogen Inorganic materials 0.000 claims description 33
- 229910052736 halogen Inorganic materials 0.000 claims description 19
- 150000002367 halogens Chemical class 0.000 claims description 19
- 239000001257 hydrogen Substances 0.000 claims description 19
- 125000001072 heteroaryl group Chemical group 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 125000003118 aryl group Chemical group 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 40
- 229910052757 nitrogen Inorganic materials 0.000 claims 27
- 125000005843 halogen group Chemical group 0.000 claims 26
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 17
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 17
- 125000005842 heteroatom Chemical group 0.000 claims 17
- 239000000203 mixture Substances 0.000 claims 17
- 229910052760 oxygen Inorganic materials 0.000 claims 17
- 239000001301 oxygen Chemical group 0.000 claims 17
- 229910052717 sulfur Chemical group 0.000 claims 17
- 239000011593 sulfur Chemical group 0.000 claims 17
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000000623 heterocyclic group Chemical group 0.000 claims 13
- -1 1,2-methylenedioxy Chemical group 0.000 claims 12
- 125000001118 alkylidene group Chemical group 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 7
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- CMDJAJYFXCBMBU-UHFFFAOYSA-N 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]-n-(2-fluorophenyl)acetamide Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC(=O)NC1=CC=CC=C1F CMDJAJYFXCBMBU-UHFFFAOYSA-N 0.000 claims 4
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 3
- GLQIZLCZHSQBLY-UHFFFAOYSA-N 2-(1h-benzimidazol-2-yl)-4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1C1=NC2=CC=CC=C2N1 GLQIZLCZHSQBLY-UHFFFAOYSA-N 0.000 claims 2
- OIIBRYKPFULYFU-UHFFFAOYSA-N 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]-n-(2,6-dimethylphenyl)acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1C2=CC=CC=C2N=C1C1=NON=C1N OIIBRYKPFULYFU-UHFFFAOYSA-N 0.000 claims 2
- RKDKILJBYDCMPH-UHFFFAOYSA-N 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]-n-(3,4-difluorophenyl)acetamide Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC(=O)NC1=CC=C(F)C(F)=C1 RKDKILJBYDCMPH-UHFFFAOYSA-N 0.000 claims 2
- CLAATNFGGLOUTN-UHFFFAOYSA-N 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]-n-(3,4-dimethoxyphenyl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1NC(=O)CN1C2=CC=CC=C2N=C1C1=NON=C1N CLAATNFGGLOUTN-UHFFFAOYSA-N 0.000 claims 2
- IBQVTCXZQBZBDN-UHFFFAOYSA-N 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]-n-(3-fluorophenyl)acetamide Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC(=O)NC1=CC=CC(F)=C1 IBQVTCXZQBZBDN-UHFFFAOYSA-N 0.000 claims 2
- MZAJMJXYFARZRU-UHFFFAOYSA-N 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]-n-[2-(trifluoromethyl)phenyl]acetamide Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC(=O)NC1=CC=CC=C1C(F)(F)F MZAJMJXYFARZRU-UHFFFAOYSA-N 0.000 claims 2
- DLHZNLYFGBAMAP-UHFFFAOYSA-N 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]-n-tert-butylacetamide Chemical compound N=1C2=CC=CC=C2N(CC(=O)NC(C)(C)C)C=1C1=NON=C1N DLHZNLYFGBAMAP-UHFFFAOYSA-N 0.000 claims 2
- WVJHNSPIODGZJK-UHFFFAOYSA-N 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]acetamide Chemical compound N=1C2=CC=CC=C2N(CC(=O)N)C=1C1=NON=C1N WVJHNSPIODGZJK-UHFFFAOYSA-N 0.000 claims 2
- VFLJHDYRDURZEP-UHFFFAOYSA-N 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]acetic acid Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC(O)=O VFLJHDYRDURZEP-UHFFFAOYSA-N 0.000 claims 2
- RSNMFVBZWSSWKA-UHFFFAOYSA-N 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]acetonitrile Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC#N RSNMFVBZWSSWKA-UHFFFAOYSA-N 0.000 claims 2
- PZFLXZUSYPMQHT-UHFFFAOYSA-N 2-[[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]methyl]benzonitrile Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC1=CC=CC=C1C#N PZFLXZUSYPMQHT-UHFFFAOYSA-N 0.000 claims 2
- HCRQPXYLXXLKPT-UHFFFAOYSA-N 4-(1-ethylbenzimidazol-2-yl)-1,2,5-oxadiazol-3-amine Chemical compound N=1C2=CC=CC=C2N(CC)C=1C1=NON=C1N HCRQPXYLXXLKPT-UHFFFAOYSA-N 0.000 claims 2
- ZIHIDNWPEZFEMR-UHFFFAOYSA-N 4-(1-methylbenzimidazol-2-yl)-1,2,5-oxadiazol-3-amine Chemical compound N=1C2=CC=CC=C2N(C)C=1C1=NON=C1N ZIHIDNWPEZFEMR-UHFFFAOYSA-N 0.000 claims 2
- BKGOWPYQEFOGAO-UHFFFAOYSA-N 4-(1-prop-2-ynylbenzimidazol-2-yl)-1,2,5-oxadiazol-3-amine Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC#C BKGOWPYQEFOGAO-UHFFFAOYSA-N 0.000 claims 2
- OOQLAKYHQPZMKP-UHFFFAOYSA-N 4-(1-propan-2-ylbenzimidazol-2-yl)-1,2,5-oxadiazol-3-amine Chemical compound N=1C2=CC=CC=C2N(C(C)C)C=1C1=NON=C1N OOQLAKYHQPZMKP-UHFFFAOYSA-N 0.000 claims 2
- UZZWGLMVBYGQSK-UHFFFAOYSA-N 4-(1-propylbenzimidazol-2-yl)-1,2,5-oxadiazol-3-amine Chemical compound N=1C2=CC=CC=C2N(CCC)C=1C1=NON=C1N UZZWGLMVBYGQSK-UHFFFAOYSA-N 0.000 claims 2
- PAMMUBFLEAQXAD-UHFFFAOYSA-N 4-(6-methyl-1H-benzimidazol-2-yl)-1,2,5-oxadiazol-3-amine Chemical compound N=1C2=CC(C)=CC=C2NC=1C1=NON=C1N PAMMUBFLEAQXAD-UHFFFAOYSA-N 0.000 claims 2
- KNJOGMJHNSVZCC-UHFFFAOYSA-N 4-[1-(2h-tetrazol-5-ylmethyl)benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC1=NNN=N1 KNJOGMJHNSVZCC-UHFFFAOYSA-N 0.000 claims 2
- LLDVRUBUBPSOMY-UHFFFAOYSA-N 4-[1-(cyclopropylmethyl)benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC1CC1 LLDVRUBUBPSOMY-UHFFFAOYSA-N 0.000 claims 2
- ROJIDUVOWRJHNV-UHFFFAOYSA-N 4-[1-[(2,4-dichlorophenyl)methyl]benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC1=CC=C(Cl)C=C1Cl ROJIDUVOWRJHNV-UHFFFAOYSA-N 0.000 claims 2
- GXKYZANVBKVGOS-UHFFFAOYSA-N 4-[1-[(2,6-dichlorophenyl)methyl]benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC1=C(Cl)C=CC=C1Cl GXKYZANVBKVGOS-UHFFFAOYSA-N 0.000 claims 2
- CPRADZBJYGDHHF-UHFFFAOYSA-N 4-[1-[(2-chloro-6-fluorophenyl)methyl]benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC1=C(F)C=CC=C1Cl CPRADZBJYGDHHF-UHFFFAOYSA-N 0.000 claims 2
- HIUITJWNRMJIBF-UHFFFAOYSA-N 4-[1-[(2-methylphenyl)methyl]benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine Chemical compound CC1=CC=CC=C1CN1C2=CC=CC=C2N=C1C1=NON=C1N HIUITJWNRMJIBF-UHFFFAOYSA-N 0.000 claims 2
- VHBPIHGCMKHKLE-UHFFFAOYSA-N 4-[1-[(3,4-dichlorophenyl)methyl]benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC1=CC=C(Cl)C(Cl)=C1 VHBPIHGCMKHKLE-UHFFFAOYSA-N 0.000 claims 2
- NSIJURZMDSCFBL-UHFFFAOYSA-N 4-[1-[(3-bromophenyl)methyl]benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC1=CC=CC(Br)=C1 NSIJURZMDSCFBL-UHFFFAOYSA-N 0.000 claims 2
- LAQLCMYZQGUKFA-UHFFFAOYSA-N 4-[1-[(4-chlorophenyl)methyl]benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC1=CC=C(Cl)C=C1 LAQLCMYZQGUKFA-UHFFFAOYSA-N 0.000 claims 2
- ITWVPIOKFJWICI-UHFFFAOYSA-N 4-[1-[(4-methylphenyl)methyl]benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine Chemical compound C1=CC(C)=CC=C1CN1C2=CC=CC=C2N=C1C1=NON=C1N ITWVPIOKFJWICI-UHFFFAOYSA-N 0.000 claims 2
- PQJCCZPMTJZYDF-UHFFFAOYSA-N 4-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]butanenitrile Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CCCC#N PQJCCZPMTJZYDF-UHFFFAOYSA-N 0.000 claims 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Natural products C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 2
- 125000004423 acyloxy group Chemical group 0.000 claims 2
- 125000005605 benzo group Chemical group 0.000 claims 2
- QEPDSNAEMKSMGN-UHFFFAOYSA-N chembl1329127 Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1 QEPDSNAEMKSMGN-UHFFFAOYSA-N 0.000 claims 2
- 125000003838 furazanyl group Chemical group 0.000 claims 2
- IKUGCHSAVSKMEA-UHFFFAOYSA-N n-[2-(1h-benzimidazol-2-yl)phenyl]acetamide Chemical compound CC(=O)NC1=CC=CC=C1C1=NC2=CC=CC=C2N1 IKUGCHSAVSKMEA-UHFFFAOYSA-N 0.000 claims 2
- VPCQBVROXHOCLQ-UHFFFAOYSA-N n-[2-(1h-benzimidazol-2-yl)phenyl]propanamide Chemical compound CCC(=O)NC1=CC=CC=C1C1=NC2=CC=CC=C2N1 VPCQBVROXHOCLQ-UHFFFAOYSA-N 0.000 claims 2
- LGXJGCZIHDEMDL-UHFFFAOYSA-N n-[4-(1-ethylbenzimidazol-2-yl)-1,2,5-oxadiazol-3-yl]-2,2,2-trifluoroacetamide Chemical compound N=1C2=CC=CC=C2N(CC)C=1C1=NON=C1NC(=O)C(F)(F)F LGXJGCZIHDEMDL-UHFFFAOYSA-N 0.000 claims 2
- XUYDLORMICPNES-UHFFFAOYSA-N n-[4-[1-(cyanomethyl)benzimidazol-2-yl]-1,2,5-oxadiazol-3-yl]acetamide Chemical compound CC(=O)NC1=NON=C1C1=NC2=CC=CC=C2N1CC#N XUYDLORMICPNES-UHFFFAOYSA-N 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- FAIVIYCNLYZSDO-UHFFFAOYSA-N 4-(1-benzylbenzimidazol-2-yl)-1,2,5-oxadiazol-3-amine Chemical compound NC1=NON=C1C1=NC2=CC=CC=C2N1CC1=CC=CC=C1 FAIVIYCNLYZSDO-UHFFFAOYSA-N 0.000 claims 1
- NYUVVVDGKCTKKF-UHFFFAOYSA-N 4-[1-(2-methylpropyl)benzimidazol-2-yl]-1,2,5-oxadiazol-3-amine Chemical compound N=1C2=CC=CC=C2N(CC(C)C)C=1C1=NON=C1N NYUVVVDGKCTKKF-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 claims 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims 1
- 102000036243 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Human genes 0.000 claims 1
- 108010002481 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Proteins 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- MEXYDCGTNFLIOA-UHFFFAOYSA-N ethyl 2-[2-(4-amino-1,2,5-oxadiazol-3-yl)benzimidazol-1-yl]acetate Chemical compound N=1C2=CC=CC=C2N(CC(=O)OCC)C=1C1=NON=C1N MEXYDCGTNFLIOA-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- OLGMRMJENRKJRP-UHFFFAOYSA-N n-[2-(1h-benzimidazol-2-yl)phenyl]-2-methylpropanamide Chemical compound CC(C)C(=O)NC1=CC=CC=C1C1=NC2=CC=CC=C2N1 OLGMRMJENRKJRP-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 150000001721 carbon Chemical class 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35484302P | 2002-02-06 | 2002-02-06 | |
| PCT/US2003/003655 WO2003066629A2 (en) | 2002-02-06 | 2003-02-06 | Heteroaryl compounds useful as inhibitors of gsk-3 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010043557A Division JP2010132697A (ja) | 2002-02-06 | 2010-02-26 | Ｇｓｋ−３の阻害剤として有用なヘテロアリール化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005526028A JP2005526028A (ja) | 2005-09-02 |
| JP2005526028A5 true JP2005526028A5 (https=) | 2011-01-06 |
| JP4656838B2 JP4656838B2 (ja) | 2011-03-23 |
Family
ID=27734431
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003566002A Expired - Fee Related JP4656838B2 (ja) | 2002-02-06 | 2003-02-06 | Ｇｓｋ−３の阻害剤として有用なヘテロアリール化合物 |
| JP2010043557A Pending JP2010132697A (ja) | 2002-02-06 | 2010-02-26 | Ｇｓｋ−３の阻害剤として有用なヘテロアリール化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010043557A Pending JP2010132697A (ja) | 2002-02-06 | 2010-02-26 | Ｇｓｋ−３の阻害剤として有用なヘテロアリール化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20040034037A1 (https=) |
| EP (2) | EP1472245A2 (https=) |
| JP (2) | JP4656838B2 (https=) |
| KR (1) | KR20040084896A (https=) |
| AU (1) | AU2003215087B2 (https=) |
| CA (1) | CA2475633C (https=) |
| ES (1) | ES2437391T3 (https=) |
| MX (1) | MXPA04007697A (https=) |
| NO (1) | NO20043726L (https=) |
| PL (1) | PL372198A1 (https=) |
| RU (1) | RU2004126671A (https=) |
| SG (1) | SG159380A1 (https=) |
| WO (1) | WO2003066629A2 (https=) |
Families Citing this family (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1317450B1 (en) * | 2000-09-15 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| GB0206861D0 (en) * | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Medicaments |
| GB0206860D0 (en) * | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
| US20040002524A1 (en) * | 2002-06-24 | 2004-01-01 | Richard Chesworth | Benzimidazole compounds and their use as estrogen agonists/antagonists |
| WO2004058265A1 (en) * | 2002-12-24 | 2004-07-15 | Biofocus Plc | Compound libraries of 2,3-substituted pyrazine derivatives capable of binding to g-protein coupled receptors |
| US7329678B2 (en) * | 2003-01-28 | 2008-02-12 | Smithkline Beecham Corporation | Chemical compounds |
| JP2006520794A (ja) * | 2003-03-21 | 2006-09-14 | スミスクライン ビーチャム コーポレーション | 化合物 |
| WO2004103994A1 (en) * | 2003-05-23 | 2004-12-02 | Basilea Pharmaceutica Ag | Furazanobenzimidazoles |
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| AR045134A1 (es) * | 2003-07-29 | 2005-10-19 | Smithkline Beecham Plc | Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic |
| AU2004267094A1 (en) | 2003-08-20 | 2005-03-03 | Vertex Pharmaceuticals Incorporated | (4 -amino -1,2, 5-oxadiazol-4-yl) -hetxiroaromatic compounds useful as protein kinase inhibitors |
| EP1670466A4 (en) * | 2003-10-06 | 2007-04-25 | Glaxo Group Ltd | PREPARATION OF 1,6,7-TRISUBSTITUTED AZABENIC ZIMIDAZOLES AS KINASE-INHIBITORS |
| DE102004010194A1 (de) * | 2004-03-02 | 2005-10-13 | Aventis Pharma Deutschland Gmbh | 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln |
| DE102004010207A1 (de) | 2004-03-02 | 2005-09-15 | Aventis Pharma S.A. | Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate |
| US7868037B2 (en) | 2004-07-14 | 2011-01-11 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| EP1771169A1 (en) | 2004-07-14 | 2007-04-11 | PTC Therapeutics, Inc. | Methods for treating hepatitis c |
| US7781478B2 (en) | 2004-07-14 | 2010-08-24 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| US7772271B2 (en) | 2004-07-14 | 2010-08-10 | Ptc Therapeutics, Inc. | Methods for treating hepatitis C |
| JP2008507518A (ja) | 2004-07-22 | 2008-03-13 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｃ型肝炎を治療するためのチエノピリジン |
| US7674907B2 (en) * | 2004-07-23 | 2010-03-09 | Amgen Inc. | Furanopyridine derivatives and methods of use |
| WO2006034207A2 (en) * | 2004-09-17 | 2006-03-30 | Vanderbilt University | Use of gsk3 inhibitors in combination with radiation therapies |
| GB0422057D0 (en) * | 2004-10-05 | 2004-11-03 | Astrazeneca Ab | Novel compounds |
| US20060204980A1 (en) * | 2004-12-28 | 2006-09-14 | Altieri Dario C | Colorectal cancer therapies |
| EP1833819A1 (en) | 2004-12-30 | 2007-09-19 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases |
| WO2006070192A1 (en) | 2004-12-30 | 2006-07-06 | Astex Therapeutics Limited | Thiazole and isothiazole derivatives that modulate the acivity of cdk, gsk and aurora kynases |
| JP2008535790A (ja) * | 2005-03-03 | 2008-09-04 | サートリス ファーマシューティカルズ， インコーポレイテッド | サーチュインモジュレーターであるｎ−フェニルベンズアミド誘導体 |
| US8796280B2 (en) | 2005-04-21 | 2014-08-05 | Merck Serono, S.A. | 2,3-disubstituted pyrazinesulfonamides as CRTH2 inhibitors |
| EP1893576A4 (en) | 2005-05-27 | 2010-03-17 | Univ Kingston | TREATMENT OF PROTEIN DISORDERING |
| DE102005025225A1 (de) * | 2005-06-01 | 2006-12-07 | Sanofi-Aventis Deutschland Gmbh | Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten |
| US8088928B2 (en) | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| EP1910385B1 (en) * | 2005-08-04 | 2013-07-24 | Sirtris Pharmaceuticals, Inc. | Benzothiazoles and thiazolopyridines as sirtuin modulators |
| US7855289B2 (en) | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| UY29823A1 (es) * | 2005-10-03 | 2007-05-31 | Astrazeneca Ab | Derivados sustituidos de 7-cloro-3h-imidazol-(4,5-b) piridina, composiciones farmacéuticas que los contienen, procesos para la preparación de los mismos y aplicaciones |
| AR055669A1 (es) * | 2005-10-03 | 2007-08-29 | Astrazeneca Ab | Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales. |
| US7625890B2 (en) | 2005-11-10 | 2009-12-01 | Smithkline Beecham Corp. | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors |
| EP1968579A1 (en) | 2005-12-30 | 2008-09-17 | Astex Therapeutics Limited | Pharmaceutical compounds |
| CA2656157A1 (en) * | 2006-06-23 | 2008-10-30 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
| RU2424233C2 (ru) * | 2006-06-29 | 2011-07-20 | Ф.Хоффманн-Ля Рош Аг | Производные бензимидазола, методы их получения, применение их в качестве агонистов фарнезоид-х-рецептора (fxr) и содержащие их фармацевтические препараты |
| EP2049119A2 (en) | 2006-06-29 | 2009-04-22 | Astex Therapeutics Limited | Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morphoolin-4-ylmethyl-1h-benzoimidazol-2-yl)-1h-1-pyrazol-4-yl]-urea |
| US20080249081A1 (en) * | 2006-10-24 | 2008-10-09 | Roger Olsson | Compounds for the treatment of pain and screening methods therefor |
| CA2668744C (en) * | 2006-11-17 | 2015-09-15 | Queen's University At Kingston | Compounds and methods for treating protein folding disorders |
| SG144809A1 (en) | 2007-01-11 | 2008-08-28 | Millipore U K Ltd | Benzimidazole compounds and their use as chromatographic ligands |
| UY30892A1 (es) * | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| TW200916472A (en) | 2007-06-20 | 2009-04-16 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
| GB0713259D0 (en) * | 2007-07-09 | 2007-08-15 | Astrazeneca Ab | Pyrazine derivatives 954 |
| WO2009024825A1 (en) * | 2007-08-21 | 2009-02-26 | Astrazeneca Ab | 2-pyrazinylbenzimidazole derivatives as receptor tyrosine kinase inhibitors |
| EP2188263B1 (en) * | 2007-08-27 | 2012-06-27 | F. Hoffmann-La Roche AG | Benzimidazole derivatives used as fxr agonists |
| ATE523508T1 (de) | 2007-10-25 | 2011-09-15 | Astrazeneca Ab | Für die behandlung von zellproliferativen erkrankungen geeignete pyridin- und pyrazinderivate |
| JP2011502984A (ja) * | 2007-11-01 | 2011-01-27 | サートリス ファーマシューティカルズ， インコーポレイテッド | サーチュインモジュレーターとしてのアミド誘導体 |
| CA2705138A1 (en) * | 2007-11-08 | 2009-05-14 | Sirtris Pharmaceuticals, Inc. | Solubilized thiazolopyridines |
| EP2222645B1 (en) | 2007-11-15 | 2013-03-20 | F. Hoffmann-La Roche AG | Benzimidazole derivatives and their use as fxr agonists |
| US7816540B2 (en) * | 2007-12-21 | 2010-10-19 | Hoffmann-La Roche Inc. | Carboxyl- or hydroxyl-substituted benzimidazole derivatives |
| EP2309855A4 (en) * | 2008-07-30 | 2012-06-27 | Oncotherapy Science Inc | BENZIMIDAZOLE DERIVATIVES AND GLYCOGEN SYNTHASE KINASE-3-BETA INHIBITORS CONTAINING THE SAME |
| KR20170015566A (ko) | 2008-11-10 | 2017-02-08 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｒ 키나제의 억제제로서 유용한 화합물 |
| EP2376502B1 (en) | 2008-12-19 | 2015-06-17 | GlaxoSmithKline LLC | Thiazolopyridine sirtuin modulating compounds |
| ES2663222T3 (es) | 2008-12-19 | 2018-04-11 | Vertex Pharmaceuticals Incorporated | Derivados de pirazina útiles como inhibidores de la quinasa ATR |
| US20110288142A1 (en) * | 2009-01-30 | 2011-11-24 | Chen Pingyun Y | CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
| EP2251010A1 (en) * | 2009-05-08 | 2010-11-17 | Sygnis Bioscience GmbH & Co. KG | Use of thiabendazole and derivatives thereof for the therapy of neurological conditions |
| EP3670509B1 (en) * | 2009-05-13 | 2023-04-19 | University of Virginia Patent Foundation | Inhibitors of inv(16) leukemia |
| DE102009033208A1 (de) * | 2009-07-15 | 2011-01-20 | Merck Patent Gmbh | Aminopyridinderivate |
| UA106763C2 (uk) * | 2009-07-27 | 2014-10-10 | Базілеа Фармас'Ютіка Аг | Фуразанобензимідазоли як проліки для лікування пухлинних або аутоімунних захворювань |
| WO2011022721A1 (en) * | 2009-08-21 | 2011-02-24 | Microbiotix, Inc | Inhibitors of botulinum neurotoxins |
| BR112012010738A2 (pt) | 2009-11-06 | 2019-09-24 | Univ Vanderbilt | ''aril e heteroaril sulfonas como potenciadores alostéricos de mglur4,composições e métodos de tratamento de disfunção neurológica'' |
| JP5856151B2 (ja) | 2010-05-12 | 2016-02-09 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼ阻害剤として有用な２−アミノピリジン誘導体 |
| US8969356B2 (en) | 2010-05-12 | 2015-03-03 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| JP2013529200A (ja) | 2010-05-12 | 2013-07-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| JP2013526539A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用なピラジン |
| US9630956B2 (en) | 2010-05-12 | 2017-04-25 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| JP2013526540A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| CA2803802A1 (en) | 2010-06-23 | 2011-12-29 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
| JP2014510151A (ja) | 2011-04-05 | 2014-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ（ｔｒａｋｉｎａｓｅ）阻害剤として有用なアミノピラジン化合物 |
| WO2012178124A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| WO2012178125A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| EP2723745A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| EP2554662A1 (en) | 2011-08-05 | 2013-02-06 | M Maria Pia Cosma | Methods of treatment of retinal degeneration diseases |
| EP2757884B1 (en) | 2011-09-22 | 2022-07-27 | Merck Sharp & Dohme LLC | Pyrazolopyridyl compounds as aldosterone synthase inhibitors |
| US9193724B2 (en) | 2011-09-22 | 2015-11-24 | Merck Sharp & Dohme Corp. | Triazolopyridyl compounds as aldosterone synthase inhibitors |
| WO2013043518A1 (en) | 2011-09-22 | 2013-03-28 | Merck Sharp & Dohme Corp. | Imidazopyridyl compounds as aldosterone synthase inhibitors |
| KR20140084112A (ko) | 2011-09-30 | 2014-07-04 | 버텍스 파마슈티칼스 인코포레이티드 | Ａｔｒ 키나제의 억제제로서 유용한 화합물 |
| SG10201606774UA (en) | 2011-09-30 | 2016-10-28 | Vertex Pharma | Processes for making compounds useful as inhibitors of atr kinase |
| WO2013049719A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2013049859A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors |
| WO2013071088A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| US8841450B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2013071085A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
| US8841337B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| WO2013071094A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| CA2869309C (en) | 2012-04-05 | 2021-02-09 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase and combination therapies thereof |
| JP6378171B2 (ja) | 2012-04-24 | 2018-08-22 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ｄｎａ−ｐｋ阻害剤 |
| US8999632B2 (en) | 2012-10-04 | 2015-04-07 | Vertex Pharmaceuticals Incorporated | Method for measuring ATR inhibition mediated increases in DNA damage |
| EP2903615B1 (en) | 2012-10-05 | 2021-04-07 | Merck Sharp & Dohme Corp. | 5-pyridin-3-yl-2,3-dihydro-1h-indole derivatives as aldosterone synthase (cyp11b2) inhibitors for the treatment of hypertension |
| US8912198B2 (en) | 2012-10-16 | 2014-12-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| RU2015117950A (ru) * | 2012-10-26 | 2016-12-20 | Ф. Хоффманн-Ля Рош Аг | 3,4-дизамещенный 1н-пиразол и 4,5-дизамещенный тиазол в качестве ингибиторов тирозинкиназы syk |
| SI2941432T1 (en) | 2012-12-07 | 2018-07-31 | Vertex Pharmaceuticals Incorporated | 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR |
| SI3527563T1 (sl) | 2013-03-12 | 2022-01-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
| JP2016512815A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体 |
| RU2675270C2 (ru) | 2013-10-17 | 2018-12-18 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы и содержащие их фармацевтические композиции |
| DK3077397T3 (da) | 2013-12-06 | 2019-12-16 | Vertex Pharma | 2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf |
| JO3517B1 (ar) * | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| BR112016028404A2 (pt) | 2014-06-05 | 2018-07-03 | Bayer Cropscience Aktiengesellschaft | compostos bicíclicos como pesticidas |
| PL3152212T3 (pl) | 2014-06-05 | 2020-06-15 | Vertex Pharmaceuticals Inc. | Radioznakowane pochodne związku 2-amino-6-fluoro-n-[5-fluoro-piridyn-3-ylo]-pirazolo[1,5-a]pirymidino-3-karboksamidu przydatne jako inhibitor kinazy atr, wytwarzanie tego związku i jego różnych postaci stałych |
| LT3157566T (lt) | 2014-06-17 | 2019-08-12 | Vertex Pharmaceuticals Incorporated | Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį |
| AU2015367977B9 (en) | 2014-12-24 | 2020-02-06 | Lg Chem, Ltd | Biaryl derivative as GPR120 agonist |
| HK1258570A1 (zh) | 2015-09-30 | 2019-11-15 | Vertex Pharmaceuticals Inc. | 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法 |
| EP3231434A1 (en) | 2016-04-14 | 2017-10-18 | Fundacio Centre de Regulacio Genomica | Method of treatment of parkinsonism |
| MX383856B (es) | 2016-06-14 | 2025-03-14 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de shp2. |
| RU2758669C2 (ru) | 2016-09-27 | 2021-11-01 | Вертекс Фармасьютикалз Инкорпорейтед | Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк |
| MX2021011775A (es) | 2017-04-26 | 2023-01-10 | Basilea Pharm Int Ag | Procesos para la preparacion de furazanobencimidazoles y formas cristalinas de estos. |
| WO2018217766A1 (en) | 2017-05-22 | 2018-11-29 | Whitehead Institute For Biomedical Research | Kcc2 expression enhancing compounds and uses thereof |
| CN109265451B (zh) * | 2018-10-09 | 2022-07-15 | 中国药科大学 | 丁酰胆碱酯酶选择性抑制剂及其制备方法与用途 |
| EP3920885A1 (en) | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| CN111454254B (zh) * | 2020-04-26 | 2023-06-02 | 云白药征武科技(上海)有限公司 | 一种具有含氟取代基的苯并咪唑衍生物的制备及其应用 |
| CN111423429A (zh) * | 2020-05-19 | 2020-07-17 | 江西科技师范大学 | 苯并咪唑联呋咱类系列化合物及其合成方法 |
| CN112920178A (zh) * | 2021-01-29 | 2021-06-08 | 中国药科大学 | 具有苯并咪唑结构的化合物及其制备方法与用途 |
| JP2026503588A (ja) * | 2023-01-20 | 2026-01-29 | パイロテック（ベイジン）バイオテクノロジー カンパニー リミテッド | 新規ａｌｐｋ１阻害剤 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3133081A (en) * | 1964-05-12 | J-aminoindazole derivatives | ||
| US3935183A (en) * | 1970-01-26 | 1976-01-27 | Imperial Chemical Industries Limited | Indazole-azo phenyl compounds |
| BE754242A (fr) * | 1970-07-15 | 1971-02-01 | Geigy Ag J R | Diamino-s-triazines et dinitro-s-triazines |
| US3998951A (en) * | 1974-03-13 | 1976-12-21 | Fmc Corporation | Substituted 2-arylquinazolines as fungicides |
| DE2458965C3 (de) * | 1974-12-13 | 1979-10-11 | Bayer Ag, 5090 Leverkusen | 3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel |
| DOP1981004033A (es) * | 1980-12-23 | 1990-12-29 | Ciba Geigy Ag | Procedimiento para proteger plantas de cultivo de la accion fitotoxica de herbicidas. |
| SE8102193L (sv) * | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och dess anvendning |
| SE8102194L (sv) * | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och farmaceutisk beredning innehallande denna |
| JPS58124773A (ja) * | 1982-01-20 | 1983-07-25 | Mitsui Toatsu Chem Inc | ５−メチルチオピリミジン誘導体とその製造法と農園芸用殺菌剤 |
| US5166170A (en) * | 1989-07-03 | 1992-11-24 | Hoechst-Roussel Pharmaceuticals Incorporated | 2-(aminoaryl) indoles and indolines as topical antiinflammatory agents for the treatment of skin disorders |
| US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5496826A (en) * | 1994-09-02 | 1996-03-05 | Bristol-Myers Squibb Company | Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides |
| WO1996014843A2 (en) * | 1994-11-10 | 1996-05-23 | Cor Therapeutics, Inc. | Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases |
| IL117659A (en) * | 1995-04-13 | 2000-12-06 | Dainippon Pharmaceutical Co | Substituted 2-phenyl pyrimidino amino acetamide derivative process for preparing the same and a pharmaceutical composition containing same |
| WO1997012613A1 (en) * | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| US6716575B2 (en) * | 1995-12-18 | 2004-04-06 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
| GB9619284D0 (en) * | 1996-09-16 | 1996-10-30 | Celltech Therapeutics Ltd | Chemical compounds |
| US6267952B1 (en) * | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
| BR9908004A (pt) * | 1998-02-17 | 2001-12-18 | Tularik Inc | Composto, composição e método para prevençãoou supressão de uma infecção viral |
| KR100581199B1 (ko) | 1998-06-19 | 2006-05-17 | 카이론 코포레이션 | 글리코겐 신타제 키나제 3의 억제제 |
| CA2339188A1 (en) * | 1998-08-21 | 2000-03-02 | Dupont Pharmaceuticals Company | Isoxazolo¬4,5-d|pyrimidines as crf antagonists |
| US6184226B1 (en) * | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| US6130333A (en) * | 1998-11-27 | 2000-10-10 | Monsanto Company | Bicyclic imidazolyl derivatives as phosphodiesterase inhibitors, pharmaceutical compositions and method of use |
| GB9828640D0 (en) | 1998-12-23 | 1999-02-17 | Smithkline Beecham Plc | Novel method and compounds |
| GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| DE19920936A1 (de) * | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
| GB9914258D0 (en) * | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
| SI1194425T1 (sl) * | 1999-06-23 | 2005-12-31 | Sanofi Aventis Deutschland | Substituirani benzimidazoli |
| US20020065270A1 (en) * | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
| HUP0202332A2 (en) * | 2000-02-05 | 2002-10-28 | Vertex Pharma | Pyrazole compositions useful as inhibitors of erk |
| EP1257546A1 (en) * | 2000-02-17 | 2002-11-20 | Amgen Inc. | Kinase inhibitors |
| GB0004887D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| EP1136099A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-(Indolylalkylamino)pyrimidone derivatives as GSK3beta inhibitors |
| ATE394102T1 (de) * | 2000-06-28 | 2008-05-15 | Astrazeneca Ab | Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren |
| US6613776B2 (en) * | 2000-09-15 | 2003-09-02 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6660731B2 (en) * | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| ATE335737T1 (de) * | 2000-09-15 | 2006-09-15 | Vertex Pharma | Isoxazole und ihre verwendung als erk-inhibitoren |
| US6610677B2 (en) * | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US7473691B2 (en) * | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| EP1317450B1 (en) * | 2000-09-15 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| US6716851B2 (en) * | 2000-12-12 | 2004-04-06 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof |
| DE10061863A1 (de) * | 2000-12-12 | 2002-06-13 | Basf Ag | Verfahren zur Herstellung von Triethylendiamin (TEDA) |
| EP1347972A1 (en) * | 2000-12-19 | 2003-10-01 | Smithkline Beecham Plc | Pyrazolo 3,4-c]pyridines as gsk-3 inhibitors |
| NZ526472A (en) * | 2000-12-21 | 2004-04-30 | Vertex Pharma | Pyrazole compounds useful as protein kinase inhibitors |
| MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| EP1373257B9 (en) * | 2001-03-29 | 2008-10-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| MXPA03009378A (es) * | 2001-04-13 | 2004-01-29 | Vertex Pharma | Inhibidores de cinasas c-jun n-terminales (jnk) y otras proteinas cinasas. |
| US20030096813A1 (en) * | 2001-04-20 | 2003-05-22 | Jingrong Cao | Compositions useful as inhibitors of GSK-3 |
| DE60232669D1 (de) * | 2001-04-30 | 2009-07-30 | Vertex Pharma | Inhibitoren von gsk-3 und kristallstrukturen von gsk-3beta-protein und -proteinkomplexen |
| AU2002308748A1 (en) * | 2001-05-16 | 2002-11-25 | Vertex Pharmaceuticals Incorporated | Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
| US6825190B2 (en) * | 2001-06-15 | 2004-11-30 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| WO2003004492A1 (en) * | 2001-07-03 | 2003-01-16 | Vertex Pharmaceuticals Incorporated | Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
| JP5039268B2 (ja) * | 2001-10-26 | 2012-10-03 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用 |
| DE60236322D1 (de) * | 2001-12-07 | 2010-06-17 | Vertex Pharma | Verbindungen auf pyrimidin-basis als gsk-3-hemmer |
| WO2003078423A1 (en) * | 2002-03-15 | 2003-09-25 | Vertex Pharmaceuticals, Inc. | Compositions useful as inhibitors of protein kinases |
| AU2003218215A1 (en) * | 2002-03-15 | 2003-09-29 | Vertex Pharmaceuticals, Inc. | Azolylaminoazines as inhibitors of protein kinases |
| DE60327999D1 (de) * | 2002-03-15 | 2009-07-30 | Vertex Pharma | Azolylaminoazine als inhibitoren von proteinkinasen |
| EP1485100B1 (en) * | 2002-03-15 | 2010-05-05 | Vertex Pharmaceuticals Incorporated | Azinylaminoazoles as inhibitors of protein kinases |
| US20030207873A1 (en) * | 2002-04-10 | 2003-11-06 | Edmund Harrington | Inhibitors of Src and other protein kinases |
| AU2003237121A1 (en) * | 2002-04-26 | 2003-11-10 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| MY141867A (en) * | 2002-06-20 | 2010-07-16 | Vertex Pharma | Substituted pyrimidines useful as protein kinase inhibitors |
| CA2491895C (en) * | 2002-07-09 | 2011-01-18 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| WO2004103994A1 (en) * | 2003-05-23 | 2004-12-02 | Basilea Pharmaceutica Ag | Furazanobenzimidazoles |
-
2003
- 2003-02-06 EP EP03710903A patent/EP1472245A2/en not_active Withdrawn
- 2003-02-06 RU RU2004126671/04A patent/RU2004126671A/ru not_active Application Discontinuation
- 2003-02-06 WO PCT/US2003/003655 patent/WO2003066629A2/en not_active Ceased
- 2003-02-06 SG SG200605228-6A patent/SG159380A1/en unknown
- 2003-02-06 CA CA2475633A patent/CA2475633C/en not_active Expired - Fee Related
- 2003-02-06 KR KR10-2004-7012258A patent/KR20040084896A/ko not_active Withdrawn
- 2003-02-06 ES ES10180554.7T patent/ES2437391T3/es not_active Expired - Lifetime
- 2003-02-06 JP JP2003566002A patent/JP4656838B2/ja not_active Expired - Fee Related
- 2003-02-06 EP EP10180554.7A patent/EP2322521B1/en not_active Expired - Lifetime
- 2003-02-06 MX MXPA04007697A patent/MXPA04007697A/es not_active Application Discontinuation
- 2003-02-06 US US10/360,535 patent/US20040034037A1/en not_active Abandoned
- 2003-02-06 PL PL03372198A patent/PL372198A1/xx not_active Application Discontinuation
- 2003-02-06 AU AU2003215087A patent/AU2003215087B2/en not_active Ceased
-
2004
- 2004-09-06 NO NO20043726A patent/NO20043726L/no unknown
-
2007
- 2007-07-12 US US11/776,756 patent/US20070270420A1/en not_active Abandoned
-
2010
- 2010-02-26 JP JP2010043557A patent/JP2010132697A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005526028A5 (https=) | ||
| US7678820B2 (en) | Hetero compound | |
| JP2005511608A5 (https=) | ||
| JP2012525431A5 (https=) | ||
| CA2475633A1 (en) | Heteroaryl compounds useful as inhibitors of gsk-3 | |
| JP5453312B2 (ja) | アルファ２ｂおよび／またはアルファ２ｃアドレナリンレセプターのサブタイプ選択性モジュレーターである置換アリール‐（イミダゾール）‐メチル）‐フェニル化合物 | |
| JP2015511613A5 (https=) | ||
| JP2014526500A5 (https=) | ||
| JP2008523041A5 (https=) | ||
| JP2013532713A5 (https=) | ||
| JP2004517087A5 (https=) | ||
| JP2013545798A5 (https=) | ||
| JP2013527847A5 (https=) | ||
| AU2003213783A1 (en) | Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5 | |
| JP2012528166A5 (https=) | ||
| CA2571347A1 (en) | Piperazine derivatives for the treatment of female sexual disorders | |
| TW200409636A (en) | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | |
| JP2008524246A5 (https=) | ||
| JP2007519694A5 (https=) | ||
| JP2014500322A5 (https=) | ||
| JP2006508192A5 (https=) | ||
| JP2011503230A5 (https=) | ||
| JP2018515525A5 (https=) | ||
| JP2019507788A5 (https=) | ||
| JP2017519818A5 (https=) |